![David Cavalla](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Cavalla
Founder at Exvastat Ltd.
David Cavalla active positions
Companies | Position | Start | End |
---|---|---|---|
Exvastat Ltd.
![]() Exvastat Ltd. Pharmaceuticals: MajorHealth Technology Exvastat Ltd. operates as pharmaceutical company. The firm develops treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The company was founded by David Cavalla , Charlotte Summers and Andrew McElroy in 2016 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | 2015-12-31 | - |
Chief Executive Officer | - | - | |
Founder | 2015-12-31 | - | |
Numedicus Ltd.
![]() Numedicus Ltd. BiotechnologyHealth Technology Numedicus Ltd. is a world-class drug repurposing British company founded in 2008. The private company is based in Cambridge, UK. Numedicus has identified several clinical-stage drug repurposing projects supported by method-of-use patents. The company uses therapeutic switching to identify secondary uses for existing drugs in practically all areas. David Cavalla, the founder, has 35 years of experience in various senior scientific and commercial roles within the pharmaceutical industry. He is one of the first advocates of drug repurposing and has used this strategy to create three first-in-class developmental products to have successfully passed human proof of concept clinical stages. The company's latest news includes the start of a phase II trial in severe COVID-19 patients. | Director/Board Member | 2008-12-07 | - |
Career history of David Cavalla
Former positions of David Cavalla
Companies | Position | Start | End |
---|---|---|---|
National Institute of Mental Health | Corporate Officer/Principal | - | - |
GSK Products, Inc.
![]() GSK Products, Inc. Wholesale DistributorsDistribution Services Part of Princeton American Corp., GSK Products, Inc. is a beauty and barber supply concern. The company is based in Phoenix, AZ. | Corporate Officer/Principal | - | - |
Training of David Cavalla
University of Cambridge | Doctorate Degree |
Statistics
International
United Kingdom | 4 |
United States | 3 |
Operational
Director/Board Member | 2 |
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 3 |
Consumer Services | 2 |
Distribution Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 4 |
---|---|
GSK Products, Inc.
![]() GSK Products, Inc. Wholesale DistributorsDistribution Services Part of Princeton American Corp., GSK Products, Inc. is a beauty and barber supply concern. The company is based in Phoenix, AZ. | Distribution Services |
National Institute of Mental Health | Government |
Exvastat Ltd.
![]() Exvastat Ltd. Pharmaceuticals: MajorHealth Technology Exvastat Ltd. operates as pharmaceutical company. The firm develops treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The company was founded by David Cavalla , Charlotte Summers and Andrew McElroy in 2016 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Numedicus Ltd.
![]() Numedicus Ltd. BiotechnologyHealth Technology Numedicus Ltd. is a world-class drug repurposing British company founded in 2008. The private company is based in Cambridge, UK. Numedicus has identified several clinical-stage drug repurposing projects supported by method-of-use patents. The company uses therapeutic switching to identify secondary uses for existing drugs in practically all areas. David Cavalla, the founder, has 35 years of experience in various senior scientific and commercial roles within the pharmaceutical industry. He is one of the first advocates of drug repurposing and has used this strategy to create three first-in-class developmental products to have successfully passed human proof of concept clinical stages. The company's latest news includes the start of a phase II trial in severe COVID-19 patients. | Health Technology |
- Stock Market
- Insiders
- David Cavalla
- Experience